Stifel Canada Cuts Earnings Estimates for HLS Therapeutics

HLS Therapeutics Inc. (TSE:HLS) – Analysts at Stifel Canada lowered their FY2024 EPS estimates for shares of HLS Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Stifel Canada analyst J. Keywood now forecasts that the company will post earnings of ($0.88) per share for the year, down from their prior estimate of ($0.86). The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q4 2024 earnings at ($0.15) EPS and FY2025 earnings at ($0.31) EPS.

Separately, Stifel Nicolaus dropped their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.

HLS Therapeutics Stock Performance

Shares of HLS opened at C$3.18 on Friday. HLS Therapeutics has a 1 year low of C$3.00 and a 1 year high of C$5.48. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01. The stock’s fifty day moving average price is C$3.55 and its two-hundred day moving average price is C$3.55. The firm has a market cap of C$101.09 million, a PE ratio of -3.15 and a beta of 1.07.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.